Skip to main content
. 2024 Aug 22;16(16):2915. doi: 10.3390/cancers16162915

Table 2.

ELN 2022 [13].

Risk Category Genetic Abnormality
Favorable
  • t(8;21) (q22;q22.1)/RUNX1::RUNX1T1

  • inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11

  • Mutated NPM1 wihout FLT3-ITD

  • bZIP in-frame mutated CEBPA

Intermediate
  • Mutated NPM1 with FLT3-ITD

  • Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions)

  • t(9;11) (p21.3;q23.3)/MLLT3::KMT2A

  • Cytogenetic and/or molecular abnormalities not classified as favorable or adverse

Adverse
  • t(6;9)(p23.3;q34.1)/DEK::NUP214

  • t(v;11q23.3)/KMT2A-rearranged

  • t(9;22)(q34.1;q11.2)/BCR::ABL1

  • t(8;16)(p11.2;p13.3)/KAT6A::CREBBP

  • inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1)

  • t(3q26.2;v)/MECOM(EVI1)-rearranged

  • −5 or del(5q); −7; −17/abn(17p)

  • Complex karyotype, monosomal karyotype

  • Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2

  • Mutated TP53